Acute tubulointerstitial nephritis of medicinal etiology: the focus is on antibacterial drugs

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The urgency of the problem of acute tubulo-interstitial nephritis (TIN) in the clinic of internal diseases continues to grow. The widespread and uncontrolled use of drugs, in particular antibiotics, is accompanied by a high risk of developing acute TIN, since the high metabolic load and relatively lower blood supply make the tubulointerstations of the renal tissue very vulnerable. Due to the lack of widespread renal biopsy in the CIS countries, including the Kyrgyz Republic, the prevalence and incidence of acute TIN is underestimated. The article provides data on the nephrotoxicity of a number of antibacterial drugs, which are especially popular among doctors in the CIS countries. The diagnostic value of renal biopsy in the verification of acute TIN with a progressive decline in renal function has been shown. The article presents the results of studies that have shown the therapeutic efficacy and safety of the steroids in the treatment of acute TIN. The review article presents scientific data on clinical cases of acute TIN associated with antibiotics, including their combined use. Early recognition and appropriate treatment of antibiotic-associated TIN will ultimately reduce the likelihood of developing chronic kidney disease. The data of the review article emphasize the need for a personalized approach when prescribing antibiotics, especially in the presence of comorbid situations, including in elderly and senile people.

Full Text

Restricted Access

About the authors

Ilkhom T. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; SEI HPE Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin

Author for correspondence.
Email: murkamilov.i@mail.ru
Scopus Author ID: 0000-0001-8513-9279

Dr. Sci. (Med.), Associate Professor at the Department of Faculty Therapy, Associate Professor

Kyrgyzstan, 92, Akhunbaev str. 720020, Bishkek; 44, Kiev str., 720022, Bishkek

Viktor V. Fomin

FSAEI HE First Moscow State Medical University named after I.M. Sechenov (Sechenov University)

Email: fomin_vic@mail.ru
ORCID iD: 0000-0002-2682-4417

Corresponding Member of RAS, Dr. Sci. (Med.), Professor, Head of the Department of Faculty Therapy No1, N.V. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Innovation and Clinical Activities

Russian Federation, 2, Bolshaya Pirogovskaya str., 119991, Moscow

Ibragim S. Sabirov

SEI HPE Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin

Email: sabirov_is@mail.ru
ORCID iD: 0000-0002-8387-5800

Dr.Sci. (Med.), Professor, Head of the Department of Therapy No. 2 of the Medical Faculty

Kyrgyzstan, 44, Kiev str., 720022, Bishkek

Furkat A. Yusupov

Osh State University

Email: furcat_y@mail.ru
ORCID iD: 0000-0003-0632-6653

Dr.Sci. (Med.), Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty, Osh State University, Chief Neurologist of the Southern Region of Kyrgyzstan

Kyrgyzstan, 331 Lenin str. 714000, Osh

Zina T. Satkynalieva

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: murkamilov.i@mail.ru
ORCID iD: 0000-0002-1019-8562

Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy

Kyrgyzstan, 92, Akhunbayev str Bishkek, 720020

References

  1. Хосева Е.Н., Морозова Т.Е. Экономические преимущества и слабые стороны генериков в системе лекарственного обеспечения населения в России и за рубежом. Качественная клиническая практика. 2013;(2):63–8. [Khoseva E.N., Morozova T.E. Economic advantages and weaknesses of generics in the system of drug provision of the population in Russia and abroad. Kachestven. Сlin. Prakt. 2013;(2):63–8 (In Russ.)].
  2. Downes K.J., Hayes M., Fitzgerald J.C., et al. Mechanisms of antimicrobial-induced nephrotoxicity in children. J. Antimicrob. Chemother. 2020;75(1): 1–13. https://doi.org/10.1093/jac/dkz325
  3. Councilman W.T. Acute interstitial nephritis. J. Exp. Med. 1898;3:393–420.
  4. Шулутко Б.И., Макаренко С.В. Тубулоинтерстициальные воспалительные заболевания почек. Нефрология. 2004;8(1):89–97. https://doi.org/ 10.24884/1561-6274-2004-8-1-89-97. [Shulutko B.I., Makarenko S.V. Tubulointerstitial inflammatory diseases of the kidneys. Nephrol. 2004;8(1): 89–97 (In Russ.)].
  5. Baldwin D.S., Levine B.B., McCluskey R.T., et al. Renal failure and interstitial nephritis due to penicillin and methicillin. N. Engl. J. Med. 1968;279(23):1245–52. https://doi.org/10.1056/NEJM196812052792302
  6. Моисеев В.С., Мухин Н.А. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клин. нефрология. 2014;2:4–29. [Moiseev V.S., Mukhin N.A. National recommendations. Cardiovascular Risk and Chronic Kidney Disease: Cardiac Nephroprotection Strategies. Clin. Nephrol. 2014;2:4–29 (In Russ.)].
  7. Насонов Е.Л. Прогресс ревматологии в начале XXI века. Соврем. ревматология. 2014;8(3):4–8. https://doi.org/10.14412/1996-7012-2014-3-4-8.[Nasonov E.L. Progress in rheumatology in the early 21st century. Modern Rheumatol. J. 2014;8(3):4–8 (In Russ.)].
  8. Одинцова И.Н., Писарева Л.Ф., Хряпенков А.В. Эпидемиология злокачественных новообразований в мире. Сибирский онкологический журнал. 2015;1(5):95–101. [Odintsova I.N., Pisareva L.F., Khryapenkov A.V. Worldwide cancer epidemiology. Siberian J. Oncol. 2015;1(5):95–101 (In Russ.)].
  9. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова, 9-й выпуск. Сахарный диабет. 2019;22(1 Suppl. 1):1–144. https://doi.org/10.14341/DM221S1. [Dedov I.I., Shestakova M.V., Mayorov A.Y., et al. Standards of specialized diabetes care. Ed. by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov, 9th edition. Diab. Mellit. 2019;22(1 Suppl. 1):1–144 (In Russ.)].
  10. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6–31. https://doi.org/10.26442/ 2075082X.2019.1.190179 [Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Syst. Hypertens. 2019;16(1):6–31 (In Russ.)].
  11. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Рос. кардиол. журн. 2020;25(3):149–218. https://doi.org/10.15829/1560-4071-2020-3-3786. [Kobalava Z.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clin. guidelines 2020. Rus. J. Cardiol. 2020;25(3):149–218 (In Russ.)].
  12. Бойцов С.А., Шальнова С.А., Деев А.Д. Эпидемиологическая ситуация как фактор, определяющий стратегию действий по снижению смертности в Российской Федерации. Тер. архив. 2020;92(1):4–9. https://doi.org/ 10.26442/00403660. 2020.01.000510. [Boytsov S.A., Shalnova S.A., Deev A.D. The epidemiological situation as a factor determining the strategy for reducing mortality in the Russian Federation. Ther. Arch. 2020;92(1):4–9 (In Russ.)].
  13. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014;(3):15–54. https://doi.org/10.18093/0869-0189-2014-0-3-15-54 [Chuchalin A.G., Avdeev S.N., Aysanov Z.R., et aln respiratory society. federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonol. 2014;(3):15–54 (In Russ.)].
  14. Парфенов В.А., Живолупов С.А., Никулина К.В. и др. Диагностика и лечение когнитивных нарушений у пациентов с хронической ишемией головного мозга: результаты Всероссийской неинтервенционной наблюдательной программы ДИАМАНТ. Журнал неврологии и психиатрии имени С.С. Корсакова. 2018;118(6):15–23. https://doi.org/10.17116/jnevro20181186115. [Parfenov V.A., Zhivolupov S.A., Nikulina K.V., et al. Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT. S.S. Korsakov J. Neurol. Psych.=Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018;118(6):15–23 (In Russ.)].
  15. Беляков Н.А., Рассохин В.В., Колбин А.С. и др. Эпидемиологическая, клиническая и финансовая составляющие результатов многолетней антиретровирусной терапии пациентов с ВИЧ-инфекцией. ВИЧ-инфекция и иммуносупрессии. 2019;11(4):7–19. https://doi.org/10.22328/ 2077-9828-2019-11-4-7-19. [Belyakov N.A., Rassokhin V.V., Kolbin A.S., et al. Epidemiological, clinical and financial components of results of longterm antiretroviral therapy of patients with HIV-infection. HIV Infect. Immunosuppres. Dis. 2019;11(4):7–19 (In Russ.)].
  16. Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я. и др. Новая коронавирусная инфекция (COVID-19): клинико-эпидемиологические аспекты. Архивъ внутренней медицины. 2020;10(2):87–93. https://doi.org/ 10.20514/2226-6704-2020-0-2-87-93 [Nikiforov V.V., Suranova T.G., Chernobrovkina T.Y., et al. New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects. The Russian Arch. Intern. Med. 2020;10(2):87–93 (In Russ.)].
  17. Joyce E., Glasner P., Ranganathan S., Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr. Nephrol. 2017;32:4:577–87. https://doi.org/10.1007/s00467-016-3394-5
  18. Хлебовец Н.И. Тубулоинтерстициальный нефрит у детей. Журнал Гродненского государственного медицинского университета. 2014;1:94–7. [Hlebovets N.I. Tubulointerstitial nephritis in children. J. Grodno State Medical University. 2014;1:94–7 (In Russ.)].
  19. Шилов Е.М., Нефрология. Клинические рекомендации [Электронный ресурс]. Под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. М., 2016. 816 с. [Shilov E.M., Nephrology. Clinical recommendations [Electronic resource]. Ed. EM. Shilov, A.V. Smirnov, N.L. Kozlovskaya. M., 2016. 816 р. (In Russ.)].
  20. Стяжкина С.Н., Абрамович А.А., Зарипова Л.В., Хренова А.А. Оценка заболеваемости острым тубулоинтерстициальным нефритом в БУЗ УР «1-я РКБ БУЗ УР» Ижевска. Mod. Sci. 2019;11–4:176–78. [Styazhkina S.N., Abramovich A.A., Zaripova L.V., Khrenova A.A. Estimation of the incidence of acute tubulointerstitial nephritis in BUZ UR "1 RKB BUZ UR" in Izhevsk. Mod. Sci. 2019;11–4:176–78 (In Russ.)].
  21. Зборовский А.Б., Тюренков И.Н. Осложнения фармакотерапии. Руководство для врачей. М., 2003. 313 с. [Zborovsky A.B., Tyurenkov I.N. Complications of pharmacotherapy. A Guide for Physicians. M., 2003. 331 р. (In Russ.)].
  22. Рябов С.И., Ракитянская И.А. Нефрология: Руководство для врачей: в 2 т. Том 1. Заболевание почек. СПб., 2013. 767 с. [Ryabov S.I., Rakityanskaya I.A. Nephrology: A guide for doctors: 2 toms. Volume 1. Kidney Dis. SPb. 2013. 767 р. (In Russ.)].
  23. Quigg R.J., Anand E. Tubulointerstitial Diseases. Lecture Notes Nephrology: A Comprehensive Guide to Renal Medicine. 2020. С. 245.
  24. Roy S., Awogbemi T., Holt R.C.L. Acute tubulointerstitial nephritis in children–a retrospective case series in a UK tertiary paediatric centre. BMC. Nephrol. 2020;21(1):1–6. https://doi.org/10.1186/s12882-020-1681-7
  25. Суслова К.В., Поселюгина О.Б. Клинический случай развития острого лекарственного тубулоинтерстициального нефрита на препарат де-нол. Тверской медицинский журнал. 2019;4:8–13. [Suslova K.V., Poselyugina O.B. A clinical case of the development of acute drug tubulointerstitial nephritis on preparat de nol. Tver. Med. J. 2019;4:8–13 (In Russ.)].
  26. Nast C.C. Medication-induced interstitial nephritis in the 21st century. Adv. Chron. Kidney Dis. 2017;24(2):72–9. https://doi.org/10.1053/ j.ackd.2016.11.016
  27. Praga M., Appel G.B. Clinical manifestations and diagnosis of acute interstitial nephritis. UpToDate. Wolters Kluwer Health, Philadelphia, PA. 2013.
  28. Nussbaum E.Z., Perazella M.A. Diagnosing acute interstitial nephritis: considerations for clinicians. Clin. Kidney J. 2019;12(6):808–13. https://doi.org/10.1093/ckj/sfz080
  29. Moledina D.G., Perazella M.A. Treatment of drug-induced acute tubulointerstitial nephritis: the search for better evidence. Clin. J. Am. Soc. Nephrol. 2018;13(12):1785–87. https://doi.org/10.2215/CJN.12001018
  30. Erden A., Karahan S., Bulut K., et al. A case of bismuth intoxication with irreversible renal damage. Int. J. Nephrol. Renovasc. Dis. 2013;6:241–43. https://doi.org/10.2147/IJNRD.S54818
  31. Martínez-Valenzuela L., Draibe J., Fulladosa X., et al. Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review. Int. J. Mol. Sci. 2021;22(5):2326. doi: 10.3390/ijms22052326.
  32. Дядык А.И., Куглер Т.Е. Лекарственный острый тубулоинтерстициальный нефрит. Альманах клинической медицины. 2017;45(7):586–98. doi: 10.18786/2072-0505-2017-45-7-586-598. [Dyadyk A.I., Kugler T.E. Acute drug-induced tubulointerstitial nephritis. Almanac Clin. Med. 2017;45(7):586–98 (In Russ.)].
  33. Fogazzi G.B, Ferrari B., Garigali G., et al. Urinary sediment findings in acute interstitial nephritis. Am. J. Kidney Dis. 2012;60:330–32. https://doi.org/10.1053/j.ajkd.2012.05.002
  34. Muriithi A.K., Leung N., Valeri A.M., et al. Biopsy proven acute interstitial nephritis, 1993–2011: a case series. Am. J. Kidney Dis. 2014;64:558–66. https://doi.org/10.1053/ j.ajkd.2014.04.027
  35. Wilson G.J., Kark A.L., Francis L.P., et al. The increasing rates of acute interstitial nephritis in Australia: a single centre case series. BMC. Nephrol. 2017;18:329. https://doi.org/10.1186/s12882-017-0747-7.
  36. Tekin K., Erol Y.O., Kurtulan O., et al. A case of adult-onset tubulointerstitial nephritis and uveitis syndrome presenting with granulomatous panuveitis. 2020. https://doi.org/10.4103/tjo.tjo_33_18
  37. Батюшин М.М. Острый тубулоинтерстициальный нефрит: вопросы диагностики и лечения. Справочник поликлинического врача. 2016;4: 67–9. [Batyushin M.M. Acute tubulointerstitial nephritis: issues of diagnosis and treatment. Outpatient Handbook. 2016;4:67–9 (In Russ.)].
  38. Fernandez-Juarez G., Perez J.V., Caravaca-Fontán F., et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin. J. Am. Soc. Nephrol. 2018;13(12):1851–58. https://doi.org/10.2215/ CJN.01390118
  39. Титова А.Р., Пастернак Е.Ю., Асецкая И.Л. и др. О безопасности антибактериальных препаратов, применяемых в педиатрии. Безопасность и риск фармакотерапии. 2015;2:12–22. [Titova A.R., Pasternak E.Y., Asetskaya I.L., et al. On the safety of antibacterial drugs used in pediatrics. Saf. Risk Pharmacother. 2015;2:12–22 (In Russ.)].
  40. Shehab N., Patel P.R., Srinivasan A., et al. Emergency department visits for antibiotic-associated adverse events. Clin. Infect. Dis. 2008;15;47(6):735–43. https://doi.org/10.1086/591126
  41. Rutter I.V., Cliff W. Using Machine Learning to Predict Acute Kidney Injuries Among Patients Treated with Empiric Antibiotics. 2018. https://doi.org/10.13023/ETD.2018.176
  42. Кузьмина А.В., Поливанов В.А., Асецкая И.Л., Зырянов С.К. Вопросы безопасности при использовании антибактериальных препаратов в современной клинической практике. Клин. микробиология и антимикробная химиотерапия. 2015;17(2):146–56. [Kuzmina A.V., Polivanov V.A., Asetskaya I.L., Zyryanov S.K. Safety issues when using antibacterial drugs in modern clinical practice.Medication errors associated with the use of cephalosporins. Clin. Microbiol. Antimicrob. Chemother. 2015;17(2):146–56 (In Russ.)].
  43. Страчунский Л.С., Козлов С.Н. Современная антимикробная химиотерапия. Руководство для врачей. М., 2002. 432 с. [Strachunsky L.S., Kozlov S.N. Modern antimicrobial chemotherapy. A guide for doctors. M., 2002.432 р. (In Russ.)].
  44. Demirkaya E., Atay A.A., Musabak U., et al. Ceftriaxone-related hemolysis and acute renal failure. Pediatr. Nephrol. 2006;21:5:733–36. https://doi.org/10.15829/1560-4071-2020-3-3786
  45. Plakogiannis R., Nogid A. Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: case series and review of the literature. Pharmacotherapy: J. Human Pharmacol. Drug Ther. 2007;27(10):1456–61. https://doi.org/10.1592/ phco.27.10.1456
  46. Mac K., Chavada R., Paull S., et al. Cefepime induced acute interstitial nephritis – a case report. BMC. Nephrol. 2015;16(1):15. https://doi.org/10.1186/s12882-015-0004-x
  47. Пикуза О.И., Cамороднова Е.А. Теневые стороны антибиотикотерапии у детей: о чем должен помнить педиатр. Практ. медицина. 2018;16(8):50–5. [Pikuza O.I., Samorodnova E.A. Seamy sides of antibiotic treatment in children: what should a pediatrician remember about. Pract. Med. 2018;16(8):50–5 (In Russ.)].
  48. Le Saux N., Robinson J. Aminoglycosides – alive and well in treatment of pediatric infections: a case of benefit versus risk. Off. J. Associat. Med. Microbiol. Infect. Dis. Can. 2019;4(1):1–5. https://doi.org/10.3138/jammi.2018.09.19.
  49. Bell G.M., Thomson D. Acute interstitial nephritis associated with gentamicin and lincomycin therapy. Postgraduat. Med. J. 1980;56(656):445–47. https://doi.org/10.1136/ pgmj.56.656.445
  50. Ababneh M., Harpe S., Oinonen M., et al. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect. Contr. Hosp. Epidemiol. 2012;33(6):594–601. https://doi.org/10.1086/665724
  51. Cosgrove S.E., Vigliani G.A., Fowler V.G., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 2009;48(6):713–21. https://doi.org/10.1086/597031
  52. El Rafei A., DeSimone D.C., Narichania A.D., et al. Comparison of Dual β-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis. J. Infect. 2018;77(5):398–404. https://doi.org/10.1016/j.jinf.2018.06.013
  53. Baher W., AboZeid A.A., Al-Khalek A., et al. The Possible Protective and Therapeutic Effects of Mesenchymal Stem Cells Compared to Vitamin C in Gentamicin Induced Acute Kidney Injury in Adult Rats: A Histological Study. Egyptian J. Histol. 2020;42(4):783–97. https://doi.org/10.21608/EJH.2019.11680.1111
  54. Abdelrahman R.S., Abdelmageed M.E. Renoprotective effect of celecoxib against gentamicin-induced nephrotoxicity through suppressing NFκB and caspase-3 signaling pathways in rats. Chemico-Biological Interactions. 2020;315:108863. https://doi.org/10.1016/ j.cbi.2019.108863
  55. Зайцев А. А., Синопальников А. И. Аминогликозиды с позиций современной практики лечения инфекций дыхательных путей. Леч. врач.2009;9: 18–25. [Zaitsev A.A., Sinopalnikov A.I. Aminoglycosides from the standpoint of modern practice of treating respiratory tract infections. Lechaschii Vrach. 2009;9:18–25 (In Russ.)].
  56. Бушма К.М., Спас В.В., Шапель И.А. и др. К вопросу о нефротоксичности аминогликозидов. Новости хирургии. 2009;17(1):157–62. [Bushma K.M., Spas V.V., Chapel I.A., et al. On the question of nephrotoxicity of aminoglycosides. Surg. News. 2009;17(1):157–62. (In Russ.)].
  57. Kaloyanides G.J., Bosmans J.L., De Broe M.E. Antibiotic and immunosuppression-related renal failure. Diseases of the kidney/Schrier, RW [edit.]. 1997. Р. 1115–51. https://doi.org/10067/199460151162165141
  58. Cone L.A. A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin. Clin. Ther. 1982;5(2):155–62.
  59. Xie H., Chen H., Hu Y., et al. Clindamycin-induced acute kidney injury: large biopsy case series. Am. J. Nephrol. 2013;38(3):179–83. https://doi.org/10.1159/ 000354088
  60. Motta J.C., Rodríguez C.A., Cortes C., et al. Acute tubulointerstitial nephritis due to the use of rifampicin. case report. Case Rep. 2020;6(1):44–51. https://doi.org/10.15446/ cr.v6n1.80443
  61. Labonia W., Dayan F., Yufra A., et al. MON-326 Rifampicin-induced interstitial nephritis successfully treated with steroids: a case report. Kidney Intern. Rep. 2019;4(7):S433–34. https://doi.org/10.1016/j.ekir.2019.05.1143
  62. Persico C., Rocchi A., Edefonti A., et al. The acute interstitial nephritis induced by azithromycin. NDT. Plus. 2011;4(3):218. https://doi.org/10.1093/ndtplus/sfr013
  63. Soni N., Harrington J.W., Weiss R., et al. Recurrent acute interstitial nephritis induced by azithromycin. Pediatr. Infect. Dis. J. 2004;23:965–66. https://doi.org/10.1097/01.inf.0000141753.41486.ff
  64. Moledina D.G., Perazella M.A. Drug-induced acute interstitial nephritis. Clin. J. Am. Soc. Nephrol. 2017;12(12):2046–49. https://doi.org/10.2215/CJN.07630717
  65. Liang K.V., Grande J.P., Fidler M.E., et al. Levofloxacin-induced acute interstitial nephritis. Gazzetta Medica Italiana Archivio per le Scienze Mediche. 2012;171(2):227–31.
  66. Liang K.V., Grande J.P., Fidler M.E., et al. Acute interstitial nephritis in an elderly patient: case report. Reactions Weekly. 2012;1416:28. https://doi.org/10.2165/00128415-201214160-00093
  67. Lenhart A., Kaur R., Uduman J. One ruff kidney: A case of drug induced acute interstitial nephritis after a dog bite. J. Gen. Intern. Med. 2018;33(2):583.
  68. Fong P.H., Woo K.T., Chan H.L., et al. Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis. Ann. Acad. Med. Singapore.1985;14(4):693–95.
  69. Barnick P., Stiller D., Glöckner R. Ampicillin associated acute interstitial nephritis with renal insufficiency - case report. J. Gesamte Inn. Med.1983;15;38(18):502–5.
  70. Moledina D.G., Perazella M.A. Drug-Induced Acute Interstitial Nephritis. Clin. J. Am. Soc. Nephrol. 2017;12(12):2046–49. https://doi.org/ 10.2215/CJN.07630717.
  71. Fernandez-Juarez G., Perez J.V., Caravaca-Fontán F., et al. Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis. Clin. J. Am. Soc. Nephrol. 2018;13(12):1851–58. https://doi.org/10.2215/CJN.01390118
  72. Valluri A., Hetherington L., Mcquarrie E., et al. Acute tubulointerstitial nephritis in Scotland. QJM. 2015;108(7):527–32. https://doi.org/10.1093/qjmed/hcu236
  73. Clarkson M., Giblin L., O'Connell F., et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol. Dial. Transplant. 2004;19(11):2778–83. https://doi.org/10.1093/ndt/gfh485
  74. Prendecki M., Tanna A., Salama A.D., et al. Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. Clin. Kidney J. 2017;10(2):233–9. https://doi.org/10.1093/ckj/sfw116
  75. Raza M., Hadid M., Keen C., et al. Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrol. (Carlton). 2012;17(8):748–53. https://doi.org/10.1111/j.1440-1797.2012.01648.x
  76. González E., Gutiérrez E., Galeano C., et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–6. https://doi.org/10.1038/sj.ki.5002776
  77. Kodner C.M., Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am. Fam. Physic. 2003;67(12):2527–34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies